Novo Nordisk and Hims & Hers have apparently decided that making money together beats fighting about it in court, dropping their patent infringement lawsuit after the two companies agreed that Hims would sell Novo’s branded Ozempic and Wegovy through its platform at the same price as other telehealth providers.
For Hims, which watched its stock rocket almost 50% at Monday’s opening bell, this is roughly the equivalent of getting caught shoplifting and walking out with a job offer. The company had been selling a $49 compounded knockoff of Novo’s Wegovy pill, a product Novo described as “mass illegal compounding” and the FDA called reason enough to threaten decisive action against compounding pharmacies. Hims pulled the pill. The lawsuit followed anyway. And now, somehow, the whole thing ends in a partnership.
Novo CEO Mike Doustdar told CNBC he doesn’t foresee reopening the litigation, which is the diplomatic equivalent of “we won.” Under the deal, Hims will stop advertising compounded GLP-1 drugs entirely and limit compounded versions only to cases where clinically necessary, which is the kind of sentence Hims’ lawyers probably read seventeen times before signing.
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 pick. Tap here.
The peace treaty arrives after a genuinely chaotic few months. Novo and Hims had already tried the partnership route once before, ending that collaboration just two months in after accusing Hims of deceptive marketing. Doustdar was careful to note this arrangement is “a very different situation,” which is the corporate version of “I promise this time is different” after a very public breakup.
The broader context matters here. Semaglutide’s U.S. patent runs until 2032, compounding loopholes are closing fast, and Novo has cleared its supply shortages, the original legal opening Hims exploited. Hims CEO Andrew Dudum is now pivoting to “rapidly shifting landscape” language and talking about bringing new therapies to the platform. A graceful exit dressed up as a growth strategy.
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
